1. Accili, D.; Frapier, C.; Mosthaf, L.; McKeon, C.; Elbein, C.; Permutt, A.; Ramos, E.; Lander, E.; Ullrich, A. and Taylor, I. (1989) . A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin‐resistant diabetes. The EMBO journal, 8(9): 2509-2517 .
2. Behraman, E.:, Kliegman, M. and Jenson, B.( 2000). Nelson textbook of pediatrics. 2nd ed. Philadelphia : W.B. Saunders.
3. Bhakdi,S. (1998) . Complement and atherogenesis: the unknown connection. Annals of Medicine, 30( 6): 503–507. 
4. Blake, G. and Ridker, P. Novel clinical markers of vascular wall inflammation. Circ Res., 89: 763-771.  
5. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 3;414:813-820.
6. Carroll m. and  Isenman D. (2012)  Regulation of humoral immunity by complement. Immunity, 37:199–207.
7. Cho, N.; Shaw, J.; Karuranga, S.; Huang, Y.; da Rocha Fernandes J. ; Ohlrogge, A. and Malanda, B. ( 2018). IDF   diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes  Res Clin Pract., 138:271–281.
8. Czarnywojtek , A.; Owecki , M.; Zgorzalewicz-Stachowiak , M.; Wolin ´ski ,K.; Szczepanek-Parulska, E.; Budny ,B.; Florek ,E.; ´rska-Stachura , J.; Miechowicz ,I.; Ba˛czyk ,M.; Sawicka ,N.; Dhir ,S. abd Ruchała.M.(2014).  The Role of Serum C-Reactive Protein Measured by High-Sensitive Method in Thyroid Disease . Arch. Immunol. Ther. Exp. , 62:501–509.
9. Dikeukwu, R. and Omole, O. ( 2013) The Awareness and Performance of Appropriate Foot Self-Care Practices among Diabetic Patients Attending Dr. Yusuf Dadoo Hospital. Gauteng Province, South Africa. Journal of Endocrinology, Metabolism and Diabetes of South Africa, 18(2):112-118.

10. Effoe,V.; Correa,A.; Chen,H.; Lacy,M. and Bertoni, A. (2015). High-Sensitivity C-Reactive Protein Is Associated With Incident Type 2 Diabetes Among African Americans: The Jackson Heart Study Diabetes Care., 38:1694–1700.

11. Essam,H.; Norah, S .; Afnan, E. and  Toleen, M.( 2018).Association between Complement System, Inflammatory Cytokines and Glucose Control in Obese Subjects. Curre Res Diabetes & Obes J., 5(3): 1-5.

12. Fronczyk, A.; Molęda, P.; Safranow, K.; Piechota, W. and  Majkowska, L. (2014 ). Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation. 37(2):349-357.

13. Gabay, C. and Kushner, I. (1999).Acute-phase proteins and other systemic responses to inflammation. New Engl J Med., 340: 448-454.

14. Garcia, C.; Feve, B.; Ferre, P.; Halimi, S.; Baizri, H.; Bordier, L.; Guiu. G.; Dupuy, O.; Bauduceau, B. and Mayaudon, H.( 2010). Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab.,36(5):327-38.

15. Graf, J.; Scherzer, R. ;Grunfeld C et al (2009). Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS ONE 4:e6242

16. Guh, D.; Zhang, W.; Bansback, N.; Amarsi, Z.; Birmingham. C. and Anis, A. (2009). The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 9:88–107.

17. Haffner, S . (2003). Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol., 92 (4):18-26. 

18. Hage, M.; Zantout, M. and Azar, S.( 2011). Thyroid disorders and diabetes mellitus. Journal of thyroid research, 2011:1-7.

19. Jayachandran, C. ; Suchetha, A.; Mundinamane,B.;  Apoorva S. M., Bhat,D. and Lalwani,M.(2016). Acute phase proteins . Journal of Chemical and Pharmaceutical Research, 8(2):365-370.

20. Kasuga, M. (2006 ). Insulin resistance and pancreatic β cell failure. The Journal of clinical investigation, 116(7):1756-1760.

21. Kautzky-Willer, A,; Harreiter, J. and Pacini, G. (2016). Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocrine reviews, 37(3):278-316.

22. Kinderlerer, A.; Ali, F.; Johns, M.; Lidington, E.; Leung, V.; Boyle, J.; Hamdulay, S.; Evans, P.; Haskard, D. and  Mason, J. (2008). KLF2- dependent, Shear Stress-induced Expression of CD59 a novel cytoprotective mechanism against complement-mediated injury in the vasculature. Jo Biol Chem., 283(21):14636-44.

23. Kriketos, A.; Greenfield, J.; Peake, P.; Furler, S.; Denyer, G.; Charlesworth, J. and Campbell, L. (2004). Inflammation, insulin resistance, and adiposity. A study of first-degree relatives of type 2 diabetic subjects. Diabetes Care, 27:2033-2040.

24. Muscari, A.; Antonelli, S.; Bianchi, G.; Cavrini, G.; Dapporto, S.; Ligabue, A.; Ludovico, C.;  Magalotti, D.; Poggiopollini, G.; Zoli , M. and  Pianoro Study Group.( 2007) Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care, 30(9):2362–2368.

25. Pearson,T.; Mensah, G.; Alexander, R.; Anderson, JL.; Cannon, RO.; Criqui,M.; Fadl,YY.; Fortmann, SP.; Hong, Y.; Myers, GL.; Rifai, N.; Smith, SC.;, Taubert, K.; Tracy, RP,  and Vinicor, F. (2003).  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation,107:499–511.

26. Pepys M. and Hirschfield, G.(2003). C-reactive protein: a critical update. J Clin Invest, 111:1805-1812

27. Radahmadi, M., Shadan, F., Karimian, S.M. and Nasimi, A. (2006). Effects of stress on exacerbation of diabetes mellitus, serum glucose and cortisol levels and body weight in rats. Pathophysiology, 13(1):51-55.

28. Ripsin, C.; Kang, H. and Urban, R. (2009). Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician,79(1):29-36.

29. Rudra,C.; Sorensen, T.; Leisenring, WM.; Dashow, E. and  Williams, MA.( 2007). Weight Characteristics and Height in Relation to Risk of Gestational Diabetes Mellitus. American Journal of Epidemiology, 165:302–308.

30. Savas, E.; Sahin,A.; Aksoy, S.; Tascan, A.; Sayıner, Z. and Ozkaya,M. (2016). Serum levels of inflammatory markers in patients  with thyroid. Int J Clin Exp Med., 9(2):4485-4490 .

31. Temelkova-Kurktschiev, T.; Henkel, E.; Koehler, C.; Karrei, K. and Hanefeld, M. (2002). Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia., 45(1):151. 

32. Vozarova, B.; Weyer, C.; Lindsay, RS. ; Pratley, RE.; Bogardus, C. and Tataranni, PA. (2002). High white lood cell count is

associated with a worsening of Insulin sensitivity and predicts the development of type 2 diabetes. Diabetes, 51(2): 455-461.

1. Walport, MJ. (2001). Complement—Second of  Two Parts. N Engl J Med., 344(15): 1140–1144.
2. Wlazlo, N.; van Greevenbroek, M.;, Ferreira, I.; Jansen, EJ.; Feskens, EJ. ; van der Kallen, CJ.; Schalkwijk, CG.; Bravenboer, B. and Stehouwer, CD. (2012). Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism,  61(12): 1787-1796.
3. Wu, Y.; Ding, Y.; Tanaka, Y. and Zhang, W. (2014). Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. International journal of medical sciences, 11(11): 1185-1200.